W
Won Kim
Researcher at University of California, San Francisco
Publications - 68
Citations - 3132
Won Kim is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 23, co-authored 67 publications receiving 2503 citations. Previous affiliations of Won Kim include Cornell University.
Papers
More filters
Journal ArticleDOI
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer,Eric Jonasch,Neeraj Agarwal,Sam B. Bhayani,William P Bro,Sam S. Chang,Toni K. Choueiri,Brian A. Costello,Ithaar Derweesh,Mayer Fishman,Thomas H. Gallagher,John L. Gore,Steven L. Hancock,Michael R. Harrison,Won Kim,Christos Kyriakopoulos,Chad A. LaGrange,Elaine T. Lam,Clayton Lau,M. Dror Michaelson,Thomas Olencki,Phillip M. Pierorazio,Elizabeth R. Plimack,Bruce G. Redman,Brian Shuch,Brad Somer,Guru Sonpavde,Jeffrey A. Sosman,Mary A. Dwyer,Rashmi Kumar +29 more
TL;DR: The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma.
Journal ArticleDOI
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +64 more
TL;DR: Integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches, providing a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Journal ArticleDOI
Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study
Seok Jin Kim,Ki-Hyun Kim,Byung Soo Kim,Chul Yong Kim,Cheolwon Suh,Jooryung Huh,Sang-wook Lee,Jin Seok Kim,Jaeho Cho,Gyeong Won Lee,Ki Mun Kang,Hyeon Seok Eom,Hong Ryull Pyo,Yong Chan Ahn,Young Hyeh Ko,Won Kim +15 more
TL;DR: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT, a phase II trial of concurrent chemoradiotherapy followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone.
Journal ArticleDOI
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
Shuang G. Zhao,S. Laura Chang,Nicholas Erho,Menggang Yu,Jonathan Lehrer,Mohammed Alshalalfa,Corey Speers,Matthew R. Cooperberg,Won Kim,Charles J. Ryan,Robert B. Den,Stephen J. Freedland,Edwin M. Posadas,Howard M. Sandler,Eric A. Klein,Peter C. Black,Roland Seiler,Scott A. Tomlins,Arul M. Chinnaiyan,Robert B. Jenkins,Elai Davicioni,Ashley E. Ross,Edward M. Schaeffer,Paul L. Nguyen,Peter R. Carroll,R. Jeffrey Karnes,Daniel E. Spratt,Felix Y. Feng,Felix Y. Feng +28 more
TL;DR: Luminal- and basal-like prostate cancers demonstrate divergent clinical behavior, and patients with luminal B tumors respond better to postoperative ADT than do patients with non–luminal B tumor tumors, contributing novel insight into prostate cancer biology.
Journal ArticleDOI
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
David A. Quigley,Joshi J. Alumkal,Alexander W. Wyatt,Vishal Kothari,Adam Foye,Paul Lloyd,Rahul Aggarwal,Won Kim,Eric Lu,Jacob Schwartzman,Kevin Beja,Matti Annala,Rajdeep Das,Morgan E. Diolaiti,Colin C. Pritchard,George Thomas,Scott A. Tomlins,Karen E. Knudsen,Christopher J. Lord,Charles J. Ryan,Jack F. Youngren,Tomasz M. Beer,Alan Ashworth,Eric J. Small,Felix Y. Feng +24 more
TL;DR: BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib are identified and it is shown that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PAR Pi resistance.